Compare · NVO vs SER
NVO vs SER
Side-by-side comparison of Novo Nordisk A/S (NVO) and Serina Therapeutics Inc. (SER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SER operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 6956.1x SER ($31.0M).
- Over the past year, NVO is down 29.3% and SER is down 63.9% - NVO leads by 34.6 points.
- SER has been more active in the news (9 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 2 for SER).
- Company
- Novo Nordisk A/S
- Serina Therapeutics Inc.
- Price
- $48.78+1.22%
- $2.07-2.36%
- Market cap
- $215.95B
- $31.0M
- 1M return
- +2.89%
- +11.29%
- 1Y return
- -29.29%
- -63.94%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2018
- News (4w)
- 4
- 9
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SER
- Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
- SEC Form 4 filed by Director Simon Farrell
- SEC Form 3 filed by new insider Simon Farrell
- Serina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease
- Serina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Serina Therapeutics Appoints Farrell Simon to its Board of Directors
- Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
- Director Brannan Stephen K. bought $2,030 worth of shares (1,000 units at $2.03) (SEC Form 4)
- BTIG Research initiated coverage on Serina Therapeutics with a new price target